Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nausheen Hasan

Internal Medicine Carol Stream, IL Medical Doctor

NPI 1245321207 CMS profile 283054

560 Belmont Ln, Carol Stream, IL 60188

Open in the dashboard

General payments

$8,765

605 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nausheen Hasan of Carol Stream, IL is reported in the CMS Open Payments database as having received $8,765 across 605 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $843 48
2024 General $1,196 67
2023 General $1,168 68
2022 General $1,267 97
2021 General $1,392 92
2020 General $1,416 100
2019 General $1,483 133

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nausheen Hasan
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Nausheen Hasan were reported at $843. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Nausheen Hasan Internal Medicine median Middle half National median
2019 $1,483 $159 $48–$570 $163
2020 $1,416 $119 $33–$402 $114
2021 $1,392 $135 $37–$521 $132
2022 $1,267 $141 $42–$496 $149
2023 $1,168 $149 $45–$519 $160
2024 $1,196 $154 $47–$537 $164
2025 $843 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,188 122 payments
  2. Amgen Inc. $799 50 payments
  3. Lilly USA, LLC $572 33 payments
  4. E.R. Squibb & Sons, L.L.C. $558 56 payments
  5. AstraZeneca Pharmaceuticals LP $540 31 payments
  6. Sunovion Pharmaceuticals Inc. $462 33 payments
  7. UCB, Inc. $418 21 payments
  8. Janssen Pharmaceuticals, Inc $410 28 payments
  9. GlaxoSmithKline, LLC. $384 29 payments
  10. Amarin Pharma Inc. $324 19 payments
  11. Other $3,111 183 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,652 600 payments
  2. Education $113 5 payments
Products named General payments · program years 2019–2025
  1. Ozempic $979 95 payments
  2. RYBELSUS $710 57 payments
  3. EVENITY $401 22 payments
  4. ELIQUIS $395 38 payments
  5. Prolia $350 19 payments
  6. TRELEGY ELLIPTA $341 26 payments
  7. XARELTO $335 24 payments
  8. FARXIGA $330 17 payments
  9. Kerendia $320 23 payments
  10. APTIOM $285 16 payments
  11. Other $7,123 484 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 282 drugs

Part D claims

29,043

Median for Internal Medicine: 777

Drug cost

$2,352,479

Median for Internal Medicine: $73,373

Branded share of claims

19.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 396 $286,898
Austedo Xr Deutetrabenazine Brand 107 $266,370
Eliquis Apixaban Brand 541 $239,390
Januvia Sitagliptin Phosphate Brand 146 $88,864
Xarelto Rivaroxaban Brand 198 $81,549
Trulicity Dulaglutide Brand 71 $68,363
Otezla Apremilast Brand 23 $55,152
Gemtesa Vibegron Brand 78 $47,657
Myrbetriq Mirabegron Brand 88 $46,143
Linzess Linaclotide Brand 60 $43,701

The 10 drugs with the highest cost, of 282 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$376,410

Medicare's payments for the services billed

Medicare patients

605

Average age 73

Services billed

4,904

373 women, 232 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 44%
Arthritis 42%
Depression 38%
Diabetes 37%
Ischemic heart disease 29%
Chronic kidney disease 27%
Atrial fibrillation 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $88
  • PFIZER INC. $27
$115 541 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $77
  • Lundbeck LLC $30
$107 13 —
Briviact
  • UCB, Inc. $82
$82 — —
MOUNJARO
  • Lilly USA, LLC $74
$74 15 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $69
$69 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

605 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record